These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 18284458

  • 1. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid.
    Chennuru S, Koduri J, Baumann MA.
    Intern Med J; 2008 Aug; 38(8):635-7. PubMed ID: 18284458
    [Abstract] [Full Text] [Related]

  • 2. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M, Masci G, Biancofiore G, Gullo G, Scorsetti M, Navarria P, Tancioni F, Berlusconi M, Giordano L, Santoro A.
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [Abstract] [Full Text] [Related]

  • 3. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa.
    Tanvetyanon T, Choudhury AM.
    Ann Pharmacother; 2004 Mar; 38(3):418-21. PubMed ID: 14970365
    [Abstract] [Full Text] [Related]

  • 4. Acute phase response and mineral status following low dose intravenous zoledronic acid in children.
    Munns CF, Rajab MH, Hong J, Briody J, Högler W, McQuade M, Little DG, Cowell CT.
    Bone; 2007 Sep; 41(3):366-70. PubMed ID: 17574945
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A, GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network.
    Cancer; 2008 Oct 01; 113(7):1588-95. PubMed ID: 18683218
    [Abstract] [Full Text] [Related]

  • 9. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
    Cha YJ, Lee YJ.
    Int J Clin Pharmacol Ther; 2013 Apr 01; 51(4):274-82. PubMed ID: 23357846
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML, Taylor SC, Barnett JB, Hu F, Levin A, Moravan V, O'Reilly SE.
    J Oncol Pharm Pract; 2006 Dec 01; 12(4):193-9. PubMed ID: 17156591
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
    Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z.
    Ann Pharmacother; 2005 Dec 01; 39(7-8):1194-7. PubMed ID: 15956222
    [Abstract] [Full Text] [Related]

  • 13. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul 01; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 14. Serum intact parathyroid hormone as a predictor of hypocalcaemia after total thyroidectomy.
    Soon PS, Magarey CJ, Campbell P, Jalaludin B.
    ANZ J Surg; 2005 Nov 01; 75(11):977-80. PubMed ID: 16336392
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.
    Jones SG, Dolan G, Lengyel K, Myers B.
    Br J Haematol; 2002 Nov 01; 119(2):576-7. PubMed ID: 12406106
    [No Abstract] [Full Text] [Related]

  • 18. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
    Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S.
    J Clin Oncol; 2008 Oct 01; 26(28):4634-8. PubMed ID: 18574158
    [Abstract] [Full Text] [Related]

  • 19. Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.
    Singh D, Khaira NS, Sekhon JS.
    Ann Oncol; 2004 Dec 01; 15(12):1848. PubMed ID: 15550594
    [No Abstract] [Full Text] [Related]

  • 20. Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as a mechanism of hypocalcaemia.
    Ho JW.
    Med Hypotheses; 2012 Mar 01; 78(3):377-9. PubMed ID: 22206806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.